AllianceBernstein’s Harvard Bioscience HBIO Stock Holding History

AllianceBernstein’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-36	Closed	-$2K	–	3503
2014 Q1	$2K	Sell	36 -1	-3%	-$46	﹤0.01%	3428
2013 Q4	$2K	Sell	37 -419	-92%	-$18.3K	﹤0.01%	3229
2013 Q3	$18K	Sell	456 -70	-13%	-$2.75K	﹤0.01%	3113
2013 Q2	$19K	Buy	+526	New	+$20.1K	﹤0.01%	3078

Other funds holding HBIO

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

HSA

Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein's HBIO Position: Q2 2014 in Review

AllianceBernstein sold out of Harvard Bioscience (HBIO) in Q2 2014, closing a stake of 36 shares — an estimated $2K sold.

AllianceBernstein first reported a position in HBIO in Q2 2013 and held it in 4 quarters. The position peaked at $19K in Q2 2013. 74 funds tracked by Wall St. Rank hold HBIO as of Q2 2014.

AllianceBernstein reported no remaining Harvard Bioscience position as of Q2 2014 after selling out during the quarter.
AllianceBernstein sold 36 Harvard Bioscience shares in Q2 2014, an estimated $2K.
AllianceBernstein first reported a position in Harvard Bioscience in Q2 2013 and held it in 4 quarters.
AllianceBernstein's Harvard Bioscience position peaked at $19K in Q2 2013.
74 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2014.

Based on AllianceBernstein's 13F filing for Q2 2014, filed 13 Aug 2014.